JOHN RUGGIANO: Open Payments
NPI 1609844240 · CRANSTON, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$925 in 53 payments from 10 companies in 2025. Trend: 2023 $1,136 · 2024 $1,903 · 2025 $925
Food & beverage: $925
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 14 | $326 |
| Otsuka America Pharmaceutical, Inc. | 11 | $175 |
| Lundbeck LLC | 15 | $143 |
| ABBVIE INC. | 3 | $76 |
| Collegium Pharmaceutical, Inc. | 3 | $67 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Alkermes, Inc. | 2 | $40 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Sage Therapeutics, LLC | 1 | $15 |
Products named: FANAPT, REXULTI, VRAYLAR, Jornay PM, CAPLYTA, LYBALVI, Auvelity, ABILIFY MAINTENA.
Industry payments across RI — which companies pay providers there.
